Product Usage: This product is intended for research purposes only.
All product information available on this website is for educational purposes only. Any form of bodily introduction into humans or animals is strictly prohibited by law. This product should only be handled by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
Dihexa – Powder, 500mg
During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly same as standards.
Dihexa (PNB-0408) is a synthetic heptapeptide analogue of angiotensin IV designed to interact with the hepatocyte growth factor (HGF)/c-Met signaling system. Experimental investigations have demonstrated that Dihexa modulates HGF-associated signaling pathways involved in cellular communication, synaptic regulatory mechanisms, and receptor-mediated signal transduction. Research has examined its effects on c-Met receptor activation, downstream kinase signaling networks, dendritic architecture regulation, and molecular processes associated with synaptic structure and connectivity. These characteristics make Dihexa a valuable research tool for studies of HGF/c-Met pharmacology, synaptogenesis-associated signaling pathways, receptor-mediated regulatory mechanisms, and comparative investigations of compounds influencing neuronal signaling networks.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure
Drag to rotate · scroll to zoom| Chemical Formula | C27H44N4O5 |
|---|---|
| Synonyms | PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide |
| Molar Mass | 504.67 g/mol |
| CAS Number | 1401708-83-5 |
| PubChem CID | 129010512 |
| Total Compound Content | 500 mg powder |
| Shelf Life | 36 months |
Every batch is independently lab tested for identity, purity and potency. View our lab testing program →
What is the mechanism by which Dihexa modulates HGF/c-Met signalling?
Experimental investigations indicate that Dihexa interacts with the hepatocyte growth factor (HGF)/c-Met signaling system through modulation of HGF-associated molecular interactions rather than direct activation of the c-Met receptor. Research has examined its influence on HGF-dependent signaling processes, receptor-mediated signal transduction, and downstream regulatory pathways associated with c-Met activation. This mechanism makes Dihexa a valuable tool for studies of HGF/c-Met pharmacology, growth factor signaling, and receptor-associated regulatory networks.
What research findings have generated interest in Dihexa's synaptogenesis-associated activity?
Published experimental investigations have reported effects of Dihexa on signaling pathways associated with synaptic structure, dendritic architecture regulation, and receptor-mediated mechanisms involved in synaptogenesis. These findings have generated significant research interest in the compound as a tool for investigating HGF/c-Met-associated signaling networks, synaptic regulatory processes, and molecular pathways governing neuronal connectivity. Continued mechanistic investigation remains an active area of research.
What is the relationship between Dihexa and angiotensin IV?
Dihexa was developed as a structurally modified analogue of angiotensin IV and retains key features of the parent scaffold while incorporating modifications designed to alter physicochemical and pharmacological properties. This structural relationship has made Dihexa useful for comparative investigations of angiotensin-derived compounds, structure-activity relationships, peptide-derived signaling modulators, and the molecular determinants governing receptor-associated signaling pathways.
